- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02986932
Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease (BBB-Alzheimers)
June 13, 2018 updated by: InSightec
A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier (BBB) Opening Using Transcranial MR-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in Patients With Early Alzheimer's Disease
This is a prospective, non-randomized, single-arm, feasibility study to evaluate the safety and initial effectiveness of opening of the Blood-Brain Barrier with intravenous contrast agents using the ExAblate Neuro System in patients with early stage Alzheimer's Disease.
Study Overview
Detailed Description
This study is a prospective, single-arm, non-randomized, feasibility, phase I trial to evaluate the safety of focal BBB opening using the ExAblate® Transcranial (220 kHz) system and Definity® ultrasound contrast in 6 patients with mild Alzheimer's Disease.
This phase I trial will be divided into two stages.
In the first stage, patients will undergo small volume BBB opening, establishing the minimum required sonication parameters to open the BBB, as evidenced by gadolinium enhancement on T1-weighted MRI.
Stage I is defined as a discrete region of approximately 9 mm x 9 mm area in the right frontal lobe.
Multiple sonications will be performed starting at low energy and ramping up until the BBB is observed to open.
The subjects will then be removed from the ExAblate® Neuro device and followed for safety for 30 days.
If the subject experienced BBB opening without any serious adverse effects (such as brain edema), then the subject may proceed to Stage two where a larger volume (2.5-3.0 cm) will be targeted.
Subjects will be followed for an additional 60 days for safety and preliminary effectiveness.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Probable AD consistent with NIA/AA criteria (McKhann, Alzheimer & Dementia 2011)
- Modified Hachinski Ischemia Scale (MHIS) score of <= 4.
- Mini Mental State Exam (MMSE) scores 18-28
- Short form Geriatric Depression Scale (GDS) score of <= 6
- Has a Florbetaben PET scan consistent with the presence of amyloid pathology in the proposed target region (right frontal lobe)
- Able to communicate sensations during the ExAblate® MRgFUS procedure.
Exclusion Criteria:
MRI findings:
- Active infection/inflammation
- Acute or chronic hemorrhages, specifically > 4 lobar microbleeds, and no siderosis or macrohemorrhages
- Tumor/space occupying lesion
- Meningeal enhancement
- More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp
- Clips or other metallic implanted objects in the skull or the brain, except shunts; other metallic objects implanted in body
- Significant cardiac disease or unstable hemodynamic status including:
- Uncontrolled hypertension on medication or abnormal ECG
- Medications known to increase risk of hemorrhage, (e.g.: patients should be off of aspirin or another anticoagulants for at least 7 days prior to treatment) or anticoagulants (class I and III) or off Avastin for 30 days
- History of a bleeding disorder, coagulopathy or a history of spontaneous hemorrhage or use of anticoagulants
- Abnormal coagulation profile (PLT < 100,00/μl), PT (>14 sec) or PTT (>36 sec), and INR > 1.3
- No more than 1 non-strategic lacune <1.5 cm
- Known cerebral or systemic vasculopathy
- Significant depression and at potential risk of suicide
- Known sensitivity/allergy to gadolinium (an alternative product may be used), Definity or any of its components.
- Any contraindications to MRI scanning such as metallic implants, claustrophibia or too large for MRI scanner
- Untreated, uncontrolled sleep apnea
- Impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2
- Does not have a reliable caregiver in frequent contact with the patient and can accompany the patient to the clinic and treatment or be available by telephone at designated times. Participants living in retirement homes may be included. Caregiver not willing to sign the Informed Consent Form
- Respiratory: chronic pulmonary disorders e.g. severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area, patients with a history of drug allergies, asthma or hay fever, and multiple allergies where the benefit/risk of administering Definity® is considered unfavorable by the study physicians in relation to the product monograph for Definity.
- Currently in a clinical teial involving investigational product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BBB opening
ExAblate focused ultrasound under MRI-guidance delivered through the intact human skull in conjunction with timed intravenous ultrasound contrast agents (Definity®) to temporarily and focally open the BBB.
|
Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in contrast enhancement (intensity) following BBB disruption
Time Frame: Immediately post treatment
|
Change in contrast enhancement (intensity) following BBB disruption to pre-sonication images as a comparative ratio measured in percent as read from MR images and normalized to the contralateral hemisphere
|
Immediately post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in amyloid uptake
Time Frame: 30 days after treatments
|
Change in amyloid uptake as compared to pre treatment scans in the targeted region
|
30 days after treatments
|
Adverse events
Time Frame: 90 days
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
90 days
|
MMSE - Mini Mental State Examination
Time Frame: 30 days
|
Treatment effect on patients' dementia state
|
30 days
|
ADAS-Cog - Alzheimer's Disease Assessment Scale - Cognitive Behavior subscales
Time Frame: 30 days
|
Treatment effect on patients' Alzheimer's disease symptoms
|
30 days
|
NPI - Neuropsychiatry Inventory
Time Frame: 30 days
|
Treatment effect on patients' dementia
|
30 days
|
GDS - Geriatric Depression Scale
Time Frame: 30 days
|
Treatment effect on patients' depression
|
30 days
|
ADCS-ADL - Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory
Time Frame: 30 days
|
Treatment effect on patients' activities of daily living
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nir Lipsman, MD, PhD, Sunnybrook Health Sciences Centre
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2016
Primary Completion (Actual)
December 1, 2017
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
December 6, 2016
First Submitted That Met QC Criteria
December 6, 2016
First Posted (Estimate)
December 8, 2016
Study Record Updates
Last Update Posted (Actual)
June 14, 2018
Last Update Submitted That Met QC Criteria
June 13, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AL001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on BBB opening
-
Assistance Publique - Hôpitaux de ParisBPIfrance; CarTheraCompleted
-
University of BaghdadActive, not recruitingRoot Canal Infection | Root Canal TreatmentIraq
-
InSightecCompletedGlioblastoma MultiformeKorea, Republic of
-
InSightecRecruitingAlzheimer DiseaseUnited States
-
Yonsei UniversityUnknown
-
Boston University Charles River CampusNational Institute on Disability, Independent Living, and Rehabilitation...CompletedPsychiatric DisorderUnited States
-
Umeå UniversityKuopio University Hospital; Sahlgrenska University Hospital, Sweden; Uppsala...TerminatedHydrocephalus, Normal PressureFinland, Sweden
-
InSightecFocused Ultrasound FoundationRecruiting
-
InSightecCompleted
-
Sheba Medical CenterUnknownIntra Cerebral HemorrhageIsrael